FDA Pulls CLIA Waiver Guidance, CMS To Take Lead Drafting New Criteria
This article was originally published in The Gray Sheet
Executive Summary
The Centers for Medicare & Medicaid Services will have the authority to make the final call on whether products receive CLIA waiver, according to FDAers.
You may also be interested in...
CLIA Waiver Sign-Off May Return To FDA – OIVD’s St. Pierre
HHS may decide by Nov. 1 whether to shift the delegation authority for CLIA waivers to FDA, OIVD Deputy Director for New Device Evaluation Donald St. Pierre stated at the Regulatory Affairs Professionals Society's annual conference in Baltimore Oct. 22
CLIA Waiver Sign-Off May Return To FDA – OIVD’s St. Pierre
HHS may decide by Nov. 1 whether to shift the delegation authority for CLIA waivers to FDA, OIVD Deputy Director for New Device Evaluation Donald St. Pierre stated at the Regulatory Affairs Professionals Society's annual conference in Baltimore Oct. 22
Industry CLIA Waiver Proposal Will Be Presented At CLIAC Meeting
AdvaMed plans to urge Clinical Laboratory Improvement Advisory Committee (CLIAC) members to consider harmonizing CLIA waiver requirements with elements of the European Union's In Vitro Diagnostics Directive